Desmethyl tocopherols for protecting cardiovascular tissue

a technology of desmethyl tocopherols and cardiovascular tissue, applied in the field of desmethyl tocopherols for protecting cardiovascular tissue, can solve the problems of increased risk of occlusive thrombosis, failure to normalize, and confusion in data interpretation, so as to achieve convenient delivery and safe delivery of effective doses

Inactive Publication Date: 2001-11-22
OKLAHOMA MEDICAL RES FOUND
View PDF0 Cites 44 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0037] In practice, the .gamma.-tocopherol (or other desmethyl tocopherols) would be formulated in a manner allowing safe delivery of effective doses to humans. The .gamma.-tocopherol (or other desmethyl tocopherols) can be absorbed orally by mammals and could be used by oral administration. The .gamma.-tocopherol (or other desmethyl tocopherols) could be administered topically to inflamed skin or gum/mouth or other mucosal tissue as a cream or gel, or could be inhaled as an aerosol. The relative st

Problems solved by technology

End-stage disease is characterized by ischemic damage to the heart and major perfused organs, and with increased risk of occlusive thrombus as portions of plaque disintegrate and initiate coagulation cascades.
Initial studies using relatively small populations (<100 subjects) failed to find a correlation between .alpha.-T and vascular disease, although these studies have been criticized for failure to normalize .alpha.T to lipid content, which might confound t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Desmethyl tocopherols for protecting cardiovascular tissue
  • Desmethyl tocopherols for protecting cardiovascular tissue
  • Desmethyl tocopherols for protecting cardiovascular tissue

Examples

Experimental program
Comparison scheme
Effect test

example 2

Demonstration of .alpha.KGDH Protection Against Nitrative Stress In Vivo by Gamma Tocopherol

[0041] Rat pups were injected intraperitoneally (I.P.) with .alpha.T or .gamma.T in an olive oil vehicle every other day for 30 days beginning 2 days after birth; control animals received vehicle only. Olive oil was chosen as a vehicle because of the low tocopherol content in this particular vegetable oil. A total of 15 mg tocopherol was delivered to each animal over the 30 day period; animal weight at the end of the period was approximately 90 g for all three groups. One half of each animal group was injected with a septic dose of LPS (2.5 mg / kg, I.P). After 24 H, animals were killed and organs collected. .alpha.KGDH was assayed in heart tissue and tocopherols were measured by HPLC-ECD / PDA. The supplementation paradigm was sufficient to approximately double the heart tissue level of both .alpha.T and .gamma.T [.alpha.T concentration=23.+-.12 ng / mg protein in controls vs. 48.+-.13 ng / mg in .a...

example 3

Demonstration of Endothelial Cell Protection by .gamma.-Tocopherol

[0042] Cultured ECV304 human endothelial cells were exposed to SIN-1 in the presence of 10 .mu.M .alpha.-T, 10 M .gamma.-T or 5 .mu.M of each (FIG. 5). Tocopherols were incubated with the cells for 19 hours prior to addition of SIN-1. Viability was assayed 24 hours later using a standard tetrazolium (MTT) reduction assay. These cells proved very resistant to damage by SIN-1; however, a 5 mM initial concentration of SIN-1 produced approximately 26% toxicity within 24 hours (N=5; FIG. 5). While .alpha.-T had no apparent effect on SIN-1 toxicity, .gamma.-T promoted viability somewhat and the combination of .gamma.-T with .alpha.-T (1:1 molar ratio) completely prevented SIN-1 toxicity (FIG. 5). The data suggest that .gamma.-T may protect cells in a way that .alpha.-T does not.

example 4

.gamma.T Scavenges Reactive Nitrogen Species in Smokers and Hypertensive Individuals

[0043] Smoking is recognized as a major contributing factor to heart disease and .gamma.-T reportedly decreases more than .alpha.-T in smokers. Hypertension is also a strong risk factor for heart disease. We have begun collection of data from "normal" subjects who do not currently have CAD, including smokers and nonsmokers, and hypertensive subjects. 11 of 54 volunteers from the Oklahoma City Veteran's Administration Hospital and the Oklahoma Medical Research Foundation indicated a current smoking habit. Seven subjects indicated a chronic hypertensive condition. As outlined in Table I, .gamma.-tocopherol tended to decrease in hypertensive subjects while nitration products tended to increase in both smokers and hypertensive subjects. This was the trend regardless of whether the tocopherol concentrations were normalized to plasma triglycerides (Table I).

1TABLE I Preliminary statistical data regarding p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Solubility (mass)aaaaaaaaaa
Therapeuticaaaaaaaaaa
Login to view more

Abstract

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.

Description

[0001] Priority is claimed from provisional application U.S. Ser. No. 60 / 186,455 filed on Mar. 2, 2000, and incorporated by reference herein.[0002] The present invention relates to concentrated preparations of desmethyl tocopherols, including but not restricted to gamma tocopherol (.gamma.T), which localize to lipid environments in cardiovascular tissue and scavenge reactive nitrogen species (RNS) by virtue of a phenolic structural element lacking one or more methyl substituents on the phenolic ring system. The capability to scavenge RNS imparts cardiovascular protective properties to the compound.[0003] Tocopherols are a class of lipophilic, phenolic compounds of plant origin. The major tocopherol found in mammalian tissue is alpha tocopherol (.alpha.-tocopherol or .alpha.T or vitamin E) FIG. 1, although significant quantities of demethylated (desmethyl) forms (particularly .gamma.-tocopherol or .gamma.T) FIG. 1, are also present. .alpha.-Tocopherol acts as a free radical scavenger...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/355
CPCA61K31/355
Inventor HENSLEY, KENNETH L.FLOYD, ROBERT A.
Owner OKLAHOMA MEDICAL RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap